Adlai Nortye Ltd. (NASDAQ:ANL) Short Interest Update

Adlai Nortye Ltd. (NASDAQ:ANL) was the recipient of a large growth in short interest during the month of November. As of November 15th, there was short interest totalling 4,300 shares, a growth of 38.7% from the October 31st total of 3,100 shares. Based on an average daily trading volume, of 16,100 shares, the short-interest ratio is presently 0.3 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and set a $9.00 target price on shares of Adlai Nortye in a research report on Monday, November 11th.

Adlai Nortye Trading Up 0.9 %

ANL stock traded up $0.02 during midday trading on Friday, reaching $2.23. 1,954 shares of the company’s stock traded hands, compared to its average volume of 11,709. The company has a 50-day moving average price of $2.27 and a two-hundred day moving average price of $3.69. Adlai Nortye has a 52 week low of $1.85 and a 52 week high of $17.48.

About Adlai Nortye

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.